🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

2,153 results for “Ou” Clear

  1. CLEVER PEPTIDE : Open-label, non-controlled, multicenter, dose escalation, first-in-human clinical trial to evaluate the safety, pharmacokinetics and preliminary antitumor activity of intravenous PEP-010, administered as single agent and in combination with paclitaxel or with gemcitabine in patients with recurrent and/or metastatic solid cancer

    The George Institute

    Patients with recurrent and/or metastatic solid cancer.

    phase 1 other active

    1 trial

  2. COVID-19 Therapeutic Biologic Mix - NOVAVAX COVID-19 VACCINE plus BCG Vaccine Mix for percutaneous use

    Lxo Ireland Designated Activity Company

    Covid19

    phase 1 mab active

    1 trial

  3. CPX-351

    Jazz Pharmaceuticals Ireland Limited

    Acute Myelogenous Leukemia

    phase 1 small molecule completed

    1 trial

  4. Capivasertib

    AstraZeneca

    Advanced Solid Tumours

    phase 1 small molecule completed

    1 trial

  5. Cemiplimab

    Regeneron UK Limited

    Locally Advanced Head and Neck Squamous Cell Carcinoma

    phase 1 small molecule active

    1 trial

  6. Chinese Herbal Compound Ointment

    The First People's Hospital of Lianyungang

    Atrophic Vaginitis

    phase 1 small molecule active

    1 trial

  7. Clinical research trial for evaluating different properties, such as safety, tolerability and body interaction, of a new drug called ALY688ER, administered as subcutaneous injection in healthy overweight or obese people.

    Lacuna Pharma Pty Ltd

    NASH

    phase 1 other active

    1 trial

  8. Clinical study to evaluate the safety of investigational medicinal product called AD-O51.4 in patients with advanced malignancies

    Lacuna Pharma Pty Ltd

    Patients suffering from cancer without further treatment options.

    phase 1 other active

    1 trial

  9. Comparison between ABP 234 and Keytruda® (Pembrolizumab)

    Amgen

    Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer

    phase 1 other active

    1 trial

  10. Comparison of the study drug CHF 1535 formulated with two different propellants to learn about drug levels in blood and safety after inhalation, with and without the use of the AeroChamber Plus® spacer, in healthy volunteers.

    Chiesi Farmaceutici S.p.A

    Asthma

    phase 1 other active

    1 trial

  11. Comparison of the study drug CHF 1535 formulated with two different propellants to learn about drug levels in blood and safety after inhalation, with and without the use of the Aerochamber Plus® spacer, in healthy volunteers.

    Chiesi Farmaceutici S.p.A

    Asthma and chronic obstructive pulmonary disease (COPD).

    phase 1 other active

    1 trial

  12. Control Group

    Tvardi Therapeutics

    Squamous Cell Carcinoma of Head and Neck

    phase 1 small molecule terminated

    1 trial

  13. Cypep-1

    BRIGHT MINDS BIOSCIENCES INC.

    Cutaneous Warts

    phase 1 small molecule completed

    1 trial

  14. Debio 0123, Debio 0123, Debio 0123, Debio 2513, Debio 0123, Debio 2513, Debio 0123, Debio 0123

    Alphapharm Pty Ltd

    Advanced solid tumors with CCNE1 amplification or deleterious mutations in FBXW7 or other proprietary gene

    phase 1 small molecule active

    1 trial

  15. Demcizumab

    Mereo BioPharma Group plc

    Primary Peritoneal Carcinoma

    phase 1 small molecule terminated

    1 trial

  16. Demcizumab

    Mereo BioPharma Group plc

    Non Small Cell Lung Cancer

    phase 1 small molecule completed

    1 trial

  17. Demcizumab

    Mereo BioPharma Group plc

    Locally Advanced or Metastatic Solid Tumors

    phase 1 small molecule completed

    1 trial

  18. Docetaxel

    Mereo BioPharma Group plc

    Solid Tumors

    phase 1 small molecule completed

    1 trial

  19. Dose escalation of SA030

    Suzhou Ribo Life Science Co.

    Obese

    phase 1 small molecule active

    1 trial

  20. Dose escalation trial of BNT152+153 in patients with cancer

    BioNTech SE

    Various solid tumors that are metastatic or unresectable

    phase 1 other active

    1 trial

  21. Double-Blind, Randomized, Placebo-Controlled, Phase 1b, Pharmacodynamic Trial of TEV-56192 Following a Single Intravenous Administration in Healthy Participants

    Lacuna Pharma Pty Ltd

    Pruritus

    phase 1 other active

    1 trial

  22. Drugs administration

    Hospital Authority, Hong Kong

    Rotator Cuff Tears of the Shoulder

    phase 1 small molecule active

    1 trial

  23. EBC-129

    BRIGHT MINDS BIOSCIENCES INC.

    Advanced Solid Tumours

    phase 1 small molecule active

    1 trial

  24. ECHO (Empowering Our Community & Health Outcomes)

    BRIGHT MINDS BIOSCIENCES INC.

    Smoking Cessation

    phase 1 other terminated

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources